{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T23:12:38Z","timestamp":1777417958747,"version":"3.51.4"},"reference-count":14,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2005,6,1]],"date-time":"2005-06-01T00:00:00Z","timestamp":1117584000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2005,6,1]],"date-time":"2005-06-01T00:00:00Z","timestamp":1117584000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinical-breast-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Breast Cancer"],"published-print":{"date-parts":[[2005,6]]},"DOI":"10.3816\/cbc.2005.n.018","type":"journal-article","created":{"date-parts":[[2008,9,10]],"date-time":"2008-09-10T21:07:36Z","timestamp":1221080856000},"page":"158-162","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"title":["Gemcitabine\/Capecitabine in Patients with Metastatic Breast Cancer Pretreated with Anthracyclines and Taxanes"],"prefix":"10.3816","volume":"6","author":[{"given":"Beth","family":"Andres","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jose Ignacio","family":"Mayordomo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ricardo","family":"Lara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rodrigo","family":"Lastra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eugenia","family":"Ortega","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eduardo","family":"Polo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julio","family":"Lambea","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dolores","family":"Isla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alberto","family":"Saenz-Cusi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pilar","family":"Escudero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alejandro","family":"Tres","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.3816\/CBC.2005.n.018_bib1","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1200\/JCO.2003.04.029","article-title":"Combining capecitabine and gemcitabine in patients with advanced pancreatic carcinoma: a phase I\/II trial","volume":"21","author":"Hess","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.3816\/CBC.2005.n.018_bib2","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1093\/annonc\/mdg029","article-title":"Biweekly high-dose gemcitabine alone or in combination with capecitabine in patients with metastatic pancreatic adenocarcinoma: a randomized phase II trial","volume":"14","author":"Scheithauer","year":"2003","journal-title":"Ann Oncol"},{"key":"10.3816\/CBC.2005.n.018_bib3","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1002\/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6","article-title":"Reporting results of cancer treatment","volume":"47","author":"Miller","year":"1981","journal-title":"Cancer"},{"key":"10.3816\/CBC.2005.n.018_bib4","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/BF00944177","article-title":"Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria","volume":"10","author":"Green","year":"1992","journal-title":"Invest New Drugs"},{"key":"10.3816\/CBC.2005.n.018_bib5","first-page":"10","article-title":"Cancer statistics, 2005","volume":"55","author":"Jemal","year":"2005","journal-title":"CA Cancer J Clin"},{"key":"10.3816\/CBC.2005.n.018_bib6","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1016\/S0959-8049(98)00058-6","article-title":"Desing of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissues","volume":"34","author":"Miwa","year":"1998","journal-title":"Eur J Cancer"},{"key":"10.3816\/CBC.2005.n.018_bib7","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1200\/JCO.1999.17.2.485","article-title":"Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer patients","volume":"17","author":"Blum","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.3816\/CBC.2005.n.018_bib8","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1002\/1097-0142(20011001)92:7<1759::AID-CNCR1691>3.0.CO;2-A","article-title":"Multicenter phase II study of capecitabine in taxane-pretreated metastatic breast cancer patients","volume":"92","author":"Blum","year":"2001","journal-title":"Cancer"},{"key":"10.3816\/CBC.2005.n.018_bib9","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1093\/annonc\/mdg346","article-title":"Multicenter phase II study of oral capecitabine (Xeloda(\u201c)) in patients with metastatic breast cancer relapsing after treatment with a taxane-containing therapy","volume":"14","author":"Reichardt","year":"2003","journal-title":"Ann Oncol"},{"key":"10.3816\/CBC.2005.n.018_bib10","first-page":"1088a","article-title":"Antitumor activity of combination therapy with capecitabine plus vinorelbine, and capecitabine plus gemcitabine in human tumor xenograft models","volume":"43","author":"Sawada","year":"2002","journal-title":"Proc Am Assoc Cancer Res"},{"key":"10.3816\/CBC.2005.n.018_bib11","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1200\/JCO.2002.20.2.582","article-title":"Dose-escalating study of capecitabine plus gemcitabine combination therapy in patients with advanced cancer","volume":"20","author":"Schilsky","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.3816\/CBC.2005.n.018_bib12","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1200\/JCO.1999.17.2.585","article-title":"Phase I-II study of gemcitabine and fluorouracil as a continuous infusion in patients with pancreatic cancer","volume":"17","author":"Hidalgo","year":"1999","journal-title":"J Clin Oncol"},{"issue":"suppl 6","key":"10.3816\/CBC.2005.n.018_bib13","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1634\/theoncologist.7-suppl_6-20","article-title":"Single-agent capecitabine: a reference treatment for taxane-pretreated metastatic breast cancer?","volume":"7","author":"Seidman","year":"2002","journal-title":"Oncologist"},{"key":"10.3816\/CBC.2005.n.018_bib14","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1200\/JCO.2002.09.002","article-title":"Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results","volume":"20","author":"O'Shaughnessy","year":"2002","journal-title":"J Clin Oncol"}],"container-title":["Clinical Breast Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526820911707145?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526820911707145?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T21:10:20Z","timestamp":1761513020000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1526820911707145"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,6]]},"references-count":14,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2005,6]]}},"alternative-id":["S1526820911707145"],"URL":"https:\/\/doi.org\/10.3816\/cbc.2005.n.018","relation":{},"ISSN":["1526-8209"],"issn-type":[{"value":"1526-8209","type":"print"}],"subject":[],"published":{"date-parts":[[2005,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Gemcitabine\/Capecitabine in Patients with Metastatic Breast Cancer Pretreated with Anthracyclines and Taxanes","name":"articletitle","label":"Article Title"},{"value":"Clinical Breast Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.3816\/CBC.2005.n.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2005 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}